

シンポジウム

日本薬学会 第135年会 シンポジウム 日本発 顧みられない熱帯病治療薬開発への挑戦

オーガナイザー：北 潔（東京大学大学院医学系研究科・生物医化学教室）
山田 陽城*（東京薬科大学薬学部）
(2015年3月26日㈭ 於：神戸学院大学)

Symposium in the 135th Annual Meeting of the Pharmaceutical Society of Japan The challenge of developing new treatments for NTDs originating from Japan

Organizers : Kiyoshi Kita (Department of Biomedical Chemistry, Graduate School of Medicine,
The University of Tokyo)
Haruki Yamada (School of Pharmacy, Tokyo University of Pharmacy and Life Science)
(Thursday, March 26, 2015, Kobe Gakuin University, Japan)

Abstract

African sleeping sickness, leishmaniasis, Chagas or Dengue, endemic diseases among the poor in tropical developing countries, are defined as NTDs (Neglected Tropical Diseases) because even though globally there are >1 billion patients it is difficult to develop new treatments in a profit-driven drug development system, and every year >1 million people die from these diseases. Even though Japan has contributed to international society through the discovery by Omura et al. of ivermectin for onchocerciasis, a NTD, compared to its drug discovery and development capabilities, results have been limited.

However, as evidenced by ebola, new health threats due to globalization require efficient drug development through new forms of collaboration between industry, academia and governments. Today innovative drug development mechanisms based on Product Development Partnerships (PDP) between industry, academia and governments help deliver new treatments for NTDs from compound screening to clinical trials and approval in endemic countries.

We will discuss recent trends in NTD drug development and ways of creating a new system for development of NTD treatments originating from Japan.

Key words

Neglected Tropical Diseases (NTDs), drug discovery, Product Development Partnerships (PDP), Drugs for Neglected Diseases initiative (DNDi), global health

Rinsho Hyoka (Clinical Evaluation). 2015 ; 43 : 189-233.

* 特定非営利活動法人DNDi Japan (DNDi Japan)